Reply  by Aroney, Constantine et al.
clear, over the past 15 years, that 100 mg per day is suboptimal for
the majority of patients. An increase in the CoQ 10 plasma level,
in the study by Watson et al., from 903 6 345 to 2,029 6 856
nmol/liter, converts roughly to a baseline level of 0.8 mg/ml up to
a treatment value of 1.7 mg/ml. Optimal improvement in myocar-
dial function in our own patients did not occur until we attained
blood CoQ 10 levels .2.0 mg/ml, with average blood level of 2.9
mg/ml, on an average dose of 240 mg of CoQ 10 per day (7,8).
Furthermore, it has also been our observation that maximal myocar-
dial function improvement with CoQ 10 supplementation is rarely
observed at three months, but can be achieved at six to 12 months.
In summary, Watson et al. are to be commended for their
efforts, for it is a difficult, poorly funded and often thankless task
to evaluate any natural and nonpatentable substance. I am hopeful
that these investigators and others will move forward to further our
understanding of this remarkable nutrient, which, for many of us
out here in the trenches of patient care, is rapidly showing itself to
be a safe and effective addition to our therapeutic armamentarium.
Peter H. Langsjoen, MD, FACC
1107 Doctors Drive
Tyler, Texas 75701
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REPLY
We thank Dr. Langsjoen for his interest in our report. He believes
that treatment with 100 mg/day of coenzyme Q 10 may be
inadequate and administered too late in the course of heart failure.
In contrast, 11 of 15 studies, including his own (1), of coenzyme
Q 10 in heart failure used #100 mg/day, and all but one purported
to provide clinical benefit with this dose. He also cites uncontrolled
observations (2) that an improvement in New York Heart Asso-
ciation functional class was associated with a higher daily dose of
240 mg (range 75 to 600) and suggests that early in the course of
idiopathic dilated cardiomyopathy, patients may respond to treat-
ment with coenzyme Q 10 (3). We wonder whether the almost
normal baseline left ventricular ejection fraction of 44% of patients
early in the course of their disease raises the possibility that for
some of them myocardial dysfunction might have been transient,
perhaps due to myocarditis. We took care to ensure that our
patients had established chronic cardiac failure. Langsjoen’s group
(3) also employed 100 mg/day of coenzyme Q 10, but more
importantly, they used impedance cardiography and systolic time
indexes, measurements of left ventricular systolic function that
were perhaps appropriate 15 years ago but might now be consid-
ered imprecise and obsolete.
We agree that a large, well-conducted and long-term trial of
coenzyme Q 10 would resolve any remaining uncertainties regard-
ing the efficacy of this agent. At this time, there are no clear data
proving its therapeutic effect in heart failure. Therefore, until there
is objective contemporary evidence of improvement in myocardial
function or survival, it will remain an unproven “alternative”
therapy for patients with heart failure. Sadly, as Langsjoen points
out, it is difficult to fund and conduct large trials of a “natural and
nonpatentable substance” such as coenzyme Q 10.
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Is the Lower Mortality in Patients
Treated With Aspirin and Angiotensin-
Converting Enzyme Inhibitors Due
to Decreased Norepinephrine Release?
We read with great interest the article by Leor et al. (1) supporting
the use of aspirin in patients with coronary artery disease treated
with angiotensin-converting enzyme (ACE) inhibitors. Their
study challenges the old tenet that aspirin may prevent the
cardioprotective effects of ACE inhibitors. Because ACE inhibi-
tors prolong bradykinin’s half-life, their cardioprotective effects
have been traditionally attributed to the antithrombotic and
vasodilating actions of prostacyclin released from the endothelium
by bradykinin (2). Evidence from our laboratory, however, sup-
ports the new findings of Leor et al. (1). We have recently
demonstrated that bradykinin is generated not only by the endo-
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